Combination of tofacitinib and tacrolimus therapy in refractory interstitial lung disease associated with anti-synthetase syndrome: a case series of six patients
Abstract
Objective This study aimed to assess the efficacy and safety of tofacitinib and tacrolimus (TAT) combination therapy for treating refractory interstitial lung disease (ILD) associated with anti-synthetase syndrome (ASyS-ILD). Method Patients with refractory ASyS-ILD who were treated with TAT at Wuhan No. 1 Hospital were included in the study from January 2020 to May 2024. A retrospective analysis of the clinical data from these patients is presented. Result A total of six patients, one male patient and five female patients, primarily presented with refractory ASyS-ILD. All patients experienced symptomatic relief following TAT therapy, which facilitated the successful tapering of glucocorticoids (GCs, 24.67 ± 17.42 vs. 8.34 ± 1.89, p = 0.004). After treatment, PGA, PGA-VAS, PhGA-VAS, and MMT-8 scores significantly improved, and diffusing capacity of carbon monoxide (DLCO) increased in all 6 patients. Moreover, the serum levels of creatine kinase (CK) and lactate dehydrogenase (LDH) were notably reduced, and inflammatory indices, including C-reactive protein (CRP), ferritin, and erythrocyte sedimentation rate (ESR), declined significantly in all patients after administration of TAT. Additionally, peripheral white blood cell and neutrophil counts were significantly reduced, while lymphocyte counts increased, with a markedly decreased neutrophil/lymphocyte ratio in patients with ASyS-ILD receiving treatment. However, during treatment, two patients developed herpes zoster, which…
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health. Reported size: 6 participants or records.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.